News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
GlaxoSmithKline’s Pazopanib Shows Promise in Ovarian Cancer
September 15, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, Sept 15 (Reuters) - GlaxoSmithKline's experimental drug pazopanib appears to be effective in fighting ovarian cancer, based on measurements of a biological marker used to predict tumour recurrence, researchers said on Monday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Europe
GlaxoSmithKline
MORE ON THIS TOPIC
Gene therapy
Patient Dies After Receiving Intellia’s CRISPR Gene Therapy Candidate
November 7, 2025
·
2 min read
·
Tristan Manalac
Obesity
Lilly’s Amylin Agonist Headed to Phase III After Eliciting up to 20% Weight Loss
November 6, 2025
·
3 min read
·
Heather McKenzie
IN PARTNERSHIP WITH PII
Thoughtful Tech: How Removing Technological Burdens Can Improve Clinical Trial Compliance and Patient Experience
November 6, 2025
·
1 min read
·
BioSpace Insights
Business
Basel Life Sciences Scene Embraces International Companies, Startups
November 6, 2025
·
6 min read
·
Angela Gabriel
